Oncocyte
$3.1
23
-$0.02-0.64% Today
Statistics
Day High
3.13
Day Low
3.04
52W High
4.34
52W Low
2.08
Volume
11,077
Avg. Volume
18,932
Mkt Cap
41.98M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
7NovExpected
Expected EPS
-0.436667
Actual EPS
N/A
People Also Follow
This list is based on the watchlists of people on Stock Events who follow OCX. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Guardant Health
GH
Mkt Cap3.15B
Exact Sciences
EXAS
Mkt Cap11.4B
Fulgent Genetics
FLGT
Mkt Cap683.49M
Bionano Genomics
BNGO
Mkt Cap42.14M
Pacific Biosciences of California
PACB
Mkt Cap373.36M
Illumina
ILMN
Mkt Cap20.93B
CRISPR Therapeutics
CRSP
Mkt Cap4.06B
Natera
NTRA
Mkt Cap14.63B
Analyst Ratings
4.25$Average Price Target
The highest estimate is $4.25.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%
About
Health Technology
Medical Specialties
Manufacturing
In-Vitro Diagnostic Substance Manufacturing
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Show more...
CEO
Employees
43
Country
US
ISIN
US68235C1071